On July 16, Bristol-Myers Squibb rose 3.01% in regular trading, trading at $60.405/share, with turnover of $418 million.

On the news front, the FDA on July 13 formally accepted the companys New Drug Application for Mezigdomide in combination with carfilzomib and dexamethasone for the treatment of relapsed or refractory multiple myeloma, with a PDUFA target action date set for May 13, 2027. The filing was supported by Phase 3 clinical data demonstrating that the combination therapy reduced the risk of disease progression or death by 52%, extending median progression-free survival to 18 months compared with 8.3 months for the standard-of-care arm. The overall response rate reached 80.2% versus 53.4% for the control group.

Additionally, RBC Capital Markets recently noted that Bristol-Myers Squibb is expected to deliver solid Q2 results and faces a pivotal second half with key milestones for its Milvexian anti-stroke and Cobenfy Alzheimer's candidates, while its CELMoD platform remains undervalued. The broader pharmacy sector also traded higher, with Merck up 2.76%, Eli Lilly up 1.53%, and Pfizer up 1.01%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)